Moricizine
- Atc Codes:C01BG01
- CAS Codes:29560-58-5
- PHARMGKB ID:29560-58-5
Table of contents
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Drug combinations
Chemistry
Moricizine Hydrochloride: C~22~H~25~N~3~O~4~S HCl. Mw: 463.98. (1) Carbamic acid, [10-[3-(4-morpholinyl)-l-oxopropyl]-10H-phenothiazin-2yl]-, ethyl ester, hydrochloride; (2) Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate, hydrochloride. CAS-29560-58-5.
Pharmacologic Category
Class Ic Antiarrhythmics. (ATC-Code: C01BG01).
Mechanism of action
Reduces fast inward current carried by sodium ions, shortens phase I and phase II repolarization, resulting in decreased action potential duration and effective refractory period.
Therapeutic use
Treatment of ventricular tachycardia and life-threatening ventricular arrhythmias.
Pregnancy and lactiation implications
Use with caution during pregnancy. Enters breast milk (not recommended during lactation).
Unlabeled use
Premature ventricular contractions. Complete and nonsustained ventricular tachycardia. Atrial arrhythmias.
Contraindications
Hypersensitivity to moricizine or any component of the formulation. Pre-existing second- or third-degree AV block (except in patients with functioning artificial pacemaker). Right bundle branch block when associated with left hemiblock or bifascicular block (unless functional pacemaker in place). Cardiogenic shock.
Warnings and precautions
Dose-related increases in PR and QRS intervals occur. Avoid use in cardiovascular disease, previous history of myocardial infarction, heart failure, pre-existing conduction abnormalities, and cardiomegaly. Electrolyte imbalance (especially hypokalemia or hypomagnesemia), should be corrected. Use with caution in significant hepatic impairment. Decreased trend in survival for patients receiving moricizine demonstrated.